The insulin sensitizing agent segment was the highest contributor to the market, with $1,030.5 million in 2018, and is estimated to reach $1,449.5 million by 2026, at a CAGR of 4.3% during the forecast period. The oral contraceptive segment is estimated to reach $1,235.2 million by 2026, at a CAGR of 5.7%. The insulin sensitizing agent and oral contraceptive segments collectively accounted for around 62.8% market share in 2018, with the former constituting around 35.5% share. The oral contraceptive and antiandrogens segments are expected to witness significant CAGRs of 5.7% and 5.1%, respectively, during the forecast period. The cumulative share of these two segments was 43.8% in 2018, and is anticipated to reach 46.4% by 2026.

INTRODUCTION

EXECUTIVE SUMMARY

MARKET OVERVIEW

POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS

POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY END USER

POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY REGION

COMPANY PROFILES